Screening

A family medicine specialist who works with cancer survivorship highlights findings of a study that illustrate how effective screening is and how treatment has changed.

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

Results from the MASAI clinical trial also showed that AI-assisted screening reduced screen-reading workload without increasing the rate of false-positives.

World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.

William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.

William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.

Your daily dose of the clinical news you may have missed.

ASCO GI Cancers Symposium: The Freenome blood-based test identified nearly 80% of individuals who had colorectal cancer.

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

Your daily dose of the clinical news you may have missed.

The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.

Your daily dose of the clinical news you may have missed.

A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

Your daily dose of the clinical news you may have missed.

Comments on the draft recommendation can be submitted through December 23, 2024.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.

CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.